MB-3 is a synthetic, lab-created molecule used to limit the activity of the enzyme GCN5 which reduces the accumulation of fat in heart cells that characterize arrhythmogenic cardiomyopathy – a disease that has affected young sportsmen such as Livorno soccer player Piermario Morosini and Asiago field hockey player Darcy Robinson. The discovery by a team of biologists from Eurac Research comes after several years of research in collaboration with the Medical University of Innsbruck, the Monzino Cardiology Center and the University of Milan.
"The biggest challenge is the overabundance of information"
Conversations between disciplines: interview with neurologist Peter Pramstaller and electronic engineer Roberto Monsorno.
Cardiac arrest: investigating causes
A heart disease common in young people is being researched at the cellular level